Schizophrenia Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020

GlobalData, the industry analysis specialist, has released its new report, “Schizophrenia Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the global schizophrenia therapeutics market. The report provides comprehensive information on schizophrenia therapeutics market, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global schizophrenia therapeutics market. It analyses the treatment usage patterns in the global schizophrenia therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global schizophrenia therapeutics market. It quantifies the unmet need in the global schizophrenia therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData’s analysis of the global schizophrenia therapeutics market suggests that the 2011 global market was valued at $10.9 billion; this is inclusive of the US, the UK, Germany, France, Italy, Spain, Japan, Brazil, Russia, India and China markets. The schizophrenia therapeutics market has increased at a CAGR of 4.6% during 2002-2011. The dominance of atypical antipsychotics such as Zyprexa (olanzapine), Seroquel (quetiapine), Abilify (aripiprazole), Risperdal/ Risperdal Consta and Geodon/ Zeldox (ziprasidone) is a salient feature of the schizophrenia therapeutics market in the seven major markets. The global schizophrenia therapeutics market is poised to witness a significant decline through 2020. The market is likely to register negative growth due to the patent expiry of Zyprexa, Abilify, Seroquel and Risperdal Consta. It is estimated that the patent expiries would lead to decline in the schizophrenia therapeutics market at a negative CAGR of 5.4% and reach $6.6 billion during the period 2011-2020. The clinical pipeline consists of drugs with novel mechanisms of action in Phase III of clinical development; among these cariprazine, RG1678, zicronapine are expected to be launched through 2020.

Scope

• An overview of schizophrenia therapeutics market which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines
• Annualized schizophrenia therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2002-2011 and forecast for nine years to 2020
• Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
• Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals and drug sales forecast
• Analysis of unmet need in the market and target product profile including opportunity for target product
• Technology trends analytic framework to assess strength of pipeline
• Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including dopamine and serotonin receptor antagonists, glycine transporter inhibitors, histamine antagonists, nicotine alpha7 receptor antagonists and phosphodiesterase 10a inhibitors
• An overview of the most promising drugs’ including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forecasts to 2020
• Emerging therapies covered – 10 Phase I drugs, 26 Phase II and Phase II/III drugs, 14 NDA filed and Phase III drugs, 26 preclinical and discovery drugs
• Analysis of the current and future market competition in the global schizophrenia therapeutics market therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Bayer, Novartis, Actelion and United Therapeutics Corporation
• Analysis of licensing agreements during 2008-2010 in the schizophrenia therapeutics market therapeutics market. M&A analysis includes M&A deals
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the schizophrenia therapeutics market.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global schizophrenia therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global schizophrenia therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Related Industry Reports

• Generalized Anxiety Disorders (GAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
• Tourette Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019
• Panic Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2019
• Psychotic Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2019
• Social Anxiety Disorders (SAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Schizophrenia Therapeutics - Introduction
2.1 Overview
2.2 Epidemiology
2.3 Etiology
2.4 Pathophysiology
2.5 Symptoms
2.6 Stages of Schizophrenia
2.7 Diagnosis
2.8 Treatment Algorithm
2.8.1 Schizophrenia Treatment Paradigm
2.8.2 Psychosocial Treatment
2.9 Drugs Prescribed for Schizophrenia
2.9.1 Injectable Medications
2.10 Schizophrenia Treatment - Future Landscape
2.11 GlobalData In-depth Report Guidance

3 Schizophrenia Therapeutics - Market Characterization
3.1 Global
3.1.1 Market Size
3.1.2 Drivers and Barriers
3.1.3 Forecasts
3.1.4 Drug Sales
3.2 The US
3.2.1 Market Size
3.2.2 Drivers and Barriers
3.2.3 Forecasts
3.2.4 Drug Sales
3.2.5 Pricing and Reimbursements
3.3 The UK
3.3.1 Market Size
3.3.2 Drivers and Barriers
3.3.3 Impact on the Market
3.3.4 Forecasts
3.3.5 Drug Sales
3.3.6 Pricing and Reimbursements
3.4 Germany
3.4.1 Market Size
3.4.2 Drivers and Barriers
3.4.3 Impact on the Market
3.4.4 Forecasts
3.4.5 Drug Sales
3.4.6 Pricing and Reimbursements
3.5 France
3.5.1 Market Size
3.5.2 Drivers and Barriers
3.5.3 Impact on the Market
3.5.4 Forecasts
3.5.5 Drug Sales
3.5.6 Pricing and Reimbursements
3.6 Italy
3.6.1 Market Size
3.6.2 Drivers and Barriers
3.6.3 Impact on the Market
3.6.4 Forecasts
3.6.5 Drug Sales
3.6.6 Pricing and Reimbursements
3.7 Spain
3.7.1 Market Size
3.7.2 Drivers and Barriers
3.7.3 Impact on the Market
3.7.4 Forecasts
3.7.5 Drug Sales
3.7.6 Pricing and Reimbursements
3.8 Japan
3.8.1 Market Size
3.8.2 Drivers and Barriers
3.8.3 Impact on the Market
3.8.4 Forecasts
3.8.5 Drug Sales
3.8.6 Pricing and Reimbursements
3.9 Brazil
3.9.1 Market Size
3.9.2 Drivers and Barriers
3.9.3 Impact on the Market
3.9.4 Forecasts
3.10 India
3.10.1 Market Size
3.10.2 Drivers and Barriers
3.10.3 Impact on the Market
3.10.4 Forecasts
3.11 China
3.11.1 Market Size
3.11.2 Drivers and Barriers
3.11.3 Impact on the Market
3.11.4 Forecasts
3.12 Russia
3.12.1 Market Size
3.12.2 Drivers and Barriers
3.12.3 Impact on the Market
3.12.4 Forecasts
3.13 Key Takeaway

4 Schizophrenia Therapeutics - Opportunity and Unmet Need
4.1 Key Takeaway

5 Schizophrenia Therapeutics - Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profile for the Major Marketed Products in the Schizophrenia Therapeutics Market
5.3.1 Abilify (aripiprazole)
5.3.2 Zyprexa (olanzapine)
5.3.3 Seroquel/Seroquel XR (quetiapine)
5.3.4 Geodon/Zeldox (ziprasidone)
5.3.5 Invega/ Invega Sustenna (paliperidone)
5.3.6 Latuda (lurasidone)
5.4 Key Takeaway

6 Schizophrenia Therapeutics - Pipeline Assessment
6.1 Overview
6.2 Strategic Pipeline Assessment
6.2.1 Technology Trends Analytic Framework
6.3 Schizophrenia Therapeutics - Promising Drugs under Clinical Development
6.4 Molecule Profile for Promising Drugs under Clinical Development
6.4.1 Cariprazine
6.4.2 RG1678
6.4.3 Zicronapine (Lu 31-30)
6.4.4 LY 2140023
6.4.5 OPC-34712
6.4.6 Staccato Loxapine (AZ004) (Adasuve)
6.5 Schizophrenia Therapeutics Market - Clinical Pipeline by Mechanism of Action
6.6 Schizophrenia Pipeline - Pipeline by Clinical Phases of Development
6.6.1 Schizophrenia Therapeutics - NDA Filed and Phase III Clinical Pipeline
6.6.2 Schizophrenia Therapeutics - Phase II/ III Clinical Pipeline
6.6.3 Schizophrenia Therapeutics - Phase II Clinical Pipeline
6.6.4 Schizophrenia Therapeutics - Phase I Clinical Pipeline
6.6.5 Schizophrenia Therapeutics - Preclinical and Discovery Pipeline
6.7 Key Takeaway

7 Schizophrenia Therapeutics - Clinical Trials Mapping
7.1 Clinical Trials
7.1.1 Clinical Trials by Status
7.1.2 Clinical Trials by Country
7.1.3 Clinical Trials by Phase
7.1.4 Clinical Trials by Sponsor Type
7.1.5 Clinical Trials - Leading Sponsors
7.1.6 Clinical Trials - Prominent Company Sponsors by Phase
7.2 Patient Recruitment

8 Schizophrenia Therapeutics - Implications for Future Market Competition

9 Schizophrenia Therapeutics - Future Market Players
9.1 Introduction
9.2 Pfizer Inc.
9.2.1 Business Description
9.2.2 Financial Overview
9.2.3 SWOT Analysis
9.3 H. Lundbeck A/S
9.3.1 Business Description
9.3.2 Financial Overview
9.3.3 SWOT Analysis
9.4 Gedeon Richter Plc.
9.4.1 Business Description
9.4.2 Financial Overview
9.4.3 SWOT Analysis
9.5 F. Hoffmann-La Roche Ltd
9.5.1 Business Description
9.5.2 Financial Overview
9.5.3 SWOT Analysis
9.6 Bristol-Myers Squibb Company
9.6.1 Business Description
9.6.2 Financial Overview
9.6.3 SWOT Analysis
9.7 Eli Lilly and Company
9.7.1 Business Description
9.7.2 Financial Overview
9.7.3 SWOT Analysis
9.8 Otsuka Holdings Co.
9.8.1 Business Description
9.8.2 Financial Performance
9.8.3 SWOT Analysis
9.9 Alexza Pharmaceuticals
9.9.1 Business Description
9.9.2 Financial Overview
9.9.3 SWOT Analysis

10 Schizophrenia Therapeutics - Licensing and Partnership Deals
10.1.1 Partnerships
10.1.2 Licensing Agreements
10.1.3 Terminated Licensing Agreements
10.2 Mergers & Acquisition Analysis
10.2.2 Terminated Acquisition Agreements

11 Expert Opinion
11.1 The US
11.2 The UK
11.3 Germany
11.4 France
11.5 India

12 Schizophrenia Therapeutics - Appendix
12.1 Definitions
12.2 Acronyms
12.3 Research Methodology
12.3.1 Coverage
12.3.2 Secondary Research
12.3.3 Forecasting
12.3.4 Primary Research
12.3.5 Expert Panel Validation
12.4 Contact Us
12.5 Disclaimer
12.6 Bibliography

List of Tables

Table 1: Broad Classification of Schizophrenia
Table 2: Prevalent Pool of Schizophrenia Patients in Seven Major Markets and BRIC Countries
Table 3: Overview of the ICD-10 and DSM-IV Criteria for Diagnosis of Schizophrenia
Table 4: Classification of Antipsychotics
Table 5: Key Insights
Table 6: Schizophrenia Therapeutics Market, Global, Sales Value ($m), 2002 - 2011
Table 7: Schizophrenia Therapeutics Market, Global, Sales Value ($m) by Country, 2002 - 2011
Table 8: Schizophrenia Therapeutics Market, Global, Annual Cost of Therapy ($), 2002 - 2011
Table 9: Schizophrenia Therapeutics Market, Global, Patient Volume , 2002 - 2011
Table 10: Schizophrenia Therapeutics Market, Global, Treatment Usage Patterns, 2002 - 2011
Table 11: Schizophrenia Therapeutics Market, Global, Sales Value ($m), 2011 - 2020
Table 12: Schizophrenia Therapeutics Market, Global, Sales Value ($m), 2011 - 2020
Table 13: Schizophrenia Therapeutics Market, Global, Annual Cost of Therapy ($), 2011 - 2020
Table 14: Schizophrenia Therapeutics Market, Global, Patient Volume , 2011 - 2020
Table 15: Schizophrenia Therapeutics Market, Global, Treatment Usage Patterns, 2011 - 2020
Table 16: Schizophrenia Therapeutics Market, Global, Drug Sales ($m), 2002 - 2011
Table 17: Schizophrenia Therapeutics Market, Global, Drug Sales ($m), 2011 - 2020
Table 18: Schizophrenia Therapeutics Market, The US, Sales Value ($m), 2002 - 2011
Table 19: Schizophrenia Therapeutics Market, The US, Annual Cost of Therapy ($), 2002 - 2011
Table 20: Schizophrenia Therapeutics Market, The US, Patient Volume , 2002 - 2011
Table 21: Schizophrenia Therapeutics Market, The US, Treatment Usage Patterns, 2002 - 2011
Table 22: Schizophrenia Therapeutics Market, The US, Sales Value ($m), 2011 - 2020
Table 23: Schizophrenia Therapeutics Market, The US, Annual Cost of Therapy ($), 2011 - 2020
Table 24: Schizophrenia Therapeutics Market, The US, Patient Volume, 2011 - 2020
Table 25: Schizophrenia Therapeutics Market, The US, Treatment Usage Patterns, 2011 - 2020
Table 26: Schizophrenia Therapeutics Market, The US, Drug Sales ($m), 2002 - 2011
Table 27: Schizophrenia Therapeutics Market, Rhe US, Drug Sales ($m), 2011 - 2020
Table 28: Schizophrenia Therapeutics Market, The UK, Sales Value ($m), 2002 - 2011
Table 29: Schizophrenia Therapeutics Market, The UK, Annual Cost of Therapy ($), 2002 - 2011
Table 30: Schizophrenia Therapeutics Market, The UK, Patient Volume , 2002 - 2011
Table 31: Schizophrenia Therapeutics Market, The UK, Treatment Usage Patterns, 2002 - 2011
Table 32: Schizophrenia Therapeutics Market, The UK, Sales Value ($m), 2011 - 2020
Table 33: Schizophrenia Therapeutics Market, The UK, Annual Cost of Therapy ($), 2011 - 2020
Table 34: Schizophrenia Therapeutics Market, The UK, Patient Volume , 2011 - 2020
Table 35: Schizophrenia Therapeutics Market, The UK, Treatment Usage Patterns, 2011 - 2020
Table 36: Schizophrenia Therapeutics Market, The UK, Drug Sales ($m), 2002 - 2011
Table 37: Schizophrenia Therapeutics Market, The UK, Drug Sales ($m), 2011 - 2020
Table 38: Schizophrenia Therapeutics Market, Germany, Sales Value ($m), 2002 - 2011
Table 39: Schizophrenia Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002 - 2011
Table 40: Schizophrenia Therapeutics Market, Germany, Patient Volume , 2002 - 2011
Table 41: Schizophrenia Therapeutics Market, Germany, Treatment Usage Patterns, 2002 - 2011
Table 42: Schizophrenia Therapeutics Market, Germany, Sales Value ($m), 2011 - 2020
Table 43: Schizophrenia Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011 - 2020
Table 44: Schizophrenia Therapeutics Market, Germany, Patient Volume , 2011 - 2020
Table 45: Schizophrenia Therapeutics Market, Germany, Treatment Usage Patterns, 2011 - 2020
Table 46: Schizophrenia Therapeutics Market, Germany, Drug Sales ($m), 2002 - 2011
Table 47: Schizophrenia Therapeutics Market, Germany, Drug Sales ($m), 2011 - 2020
Table 48: Schizophrenia Therapeutics Market, France, Sales Value ($m), 2002 - 2011
Table 49: Schizophrenia Therapeutics Market, France, Annual Cost of Therapy ($), 2002 - 2011
Table 50: Schizophrenia Therapeutics Market, France, Patient Volume , 2002 - 2011
Table 51: Schizophrenia Therapeutics Market, France, Treatment Usage Patterns, 2002 - 2011
Table 52: Schizophrenia Therapeutics Market, France, Sales Value ($m), 2011 - 2020
Table 53: Schizophrenia Therapeutics Market, France, Annual Cost of Therapy ($), 2011 - 2020
Table 54: Schizophrenia Therapeutics Market, France, Patient Volume, 2011 - 2020
Table 55: Schizophrenia Therapeutics Market, France, Treatment Usage Patterns, 2011 - 2020
Table 56: Schizophrenia Therapeutics Market, France, Drug Sales ($m), 2002 - 2011
Table 57: Schizophrenia Therapeutics Market, France, Drug Sales ($m), 2011 - 2020
Table 58: Schizophrenia Therapeutics Market, Italy, Sales Value ($m), 2002 - 2011
Table 59: Schizophrenia Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002 - 2011
Table 60: Schizophrenia Therapeutics Market, Italy, Patient Volume , 2002 - 2011
Table 61: Schizophrenia Therapeutics Market, Italy, Treatment Usage Patterns, 2002 - 2011
Table 62: Schizophrenia Therapeutics Market, Italy, Sales Value ($m), 2011 - 2020
Table 63: Schizophrenia Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011 - 2020
Table 64: Schizophrenia Therapeutics Market, Italy, Patient Volume , 2011 - 2020
Table 65: Schizophrenia Therapeutics Market, Italy, Treatment Usage Patterns, 2011 - 2020
Table 66: Schizophrenia Therapeutics Market, Italy, Drug Sales ($m), 2002 - 2011
Table 67: Schizophrenia Therapeutics Market, Italy, Drug Sales ($m), 2011 - 2020
Table 68: Schizophrenia Therapeutics Market, Spain, Sales Value ($m), 2002 - 2011
Table 69: Schizophrenia Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002 - 2011
Table 70: Schizophrenia Therapeutics Market, Spain, Patient Volume, 2002 - 2011
Table 71: Schizophrenia Therapeutics Market, Spain, Treatment Usage Patterns, 2002 - 2011
Table 72: Schizophrenia Therapeutics Market, Spain, Sales Value ($m), 2011 - 2020
Table 73: Schizophrenia Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011 - 2020
Table 74: Schizophrenia Therapeutics Market, Spain, Patient Volume , 2011 - 2020
Table 75: Schizophrenia Therapeutics Market, Spain, Treatment Usage Patterns, 2011 - 2020
Table 76: Schizophrenia Therapeutics Market, Spain, Drug Sales ($m), 2002 - 2011
Table 77: Schizophrenia Therapeutics Market, Spain, Drug Sales ($m), 2011 - 2020
Table 78: Schizophrenia Therapeutics Market, Japan, Sales Value ($m), 2002 - 2011
Table 79: Schizophrenia Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002 - 2011
Table 80: Schizophrenia Therapeutics Market, Japan, Patient Volume , 2002 - 2011
Table 81: Schizophrenia Therapeutics Market, Japan, Treatment Usage Patterns, 2002 - 2011
Table 82: Schizophrenia Therapeutics Market, Japan, Sales Value ($m), 2011 - 2020
Table 83: Schizophrenia Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011 - 2020
Table 84: Schizophrenia Therapeutics Market, Japan, Patient Volume , 2011 - 2020
Table 85: Schizophrenia Therapeutics Market, Japan, Treatment Usage Patterns, 2011 - 2020
Table 86: Schizophrenia Therapeutics Market, Japan, Drug Sales ($m), 2002 - 2011
Table 87: Schizophrenia Therapeutics Market, Japan, Drug Sales ($m), 2011 - 2020
Table 88: Schizophrenia Therapeutics Market, Brazil, Sales Value ($m), 2002 - 2011
Table 89: Schizophrenia Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002 - 2011
Table 90: Schizophrenia Therapeutics Market, Brazil, Patient Volume , 2002 - 2011
Table 91: Schizophrenia Therapeutics Market, Brazil, Treatment Usage Patterns, 2002 - 2011
Table 92: Schizophrenia Therapeutics Market, Brazil, Sales Value ($m), 2011 - 2020
Table 93: Schizophrenia Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011 - 2020
Table 94: Schizophrenia Therapeutics Market, Brazil, Patient Volume , 2011 - 2020
Table 95: Schizophrenia Therapeutics Market, Brazil, Treatment Usage Patterns, 2011 - 2020
Table 96: Schizophrenia Therapeutics Market, India, Sales Value ($m), 2002 - 2011
Table 97: Schizophrenia Therapeutics Market, India, Annual Cost of Therapy ($), 2002 - 2011
Table 98: Schizophrenia Therapeutics Market, India, Patient Volume , 2002 - 2011
Table 99: Schizophrenia Therapeutics Market, India, Treatment Usage Patterns, 2002 - 2011
Table 100: Schizophrenia Therapeutics Market, India, Sales Value ($m), 2011 - 2020
Table 101: Schizophrenia Therapeutics Market, India, Annual Cost of Therapy ($), 2011 - 2020
Table 102: Schizophrenia Therapeutics Market, India, Patient Volume , 2011 - 2020
Table 103: Schizophrenia Therapeutics Market, India, Treatment Usage Patterns, 2011 - 2020
Table 104: Schizophrenia Therapeutics Market, China, Sales Value ($m), 2002 - 2011
Table 105: Schizophrenia Therapeutics Market, China, Annual Cost of Therapy ($), 2002 - 2011
Table 106: Schizophrenia Therapeutics Market, China, Patient Volume , 2002 - 2011
Table 107: Schizophrenia Therapeutics Market, China, Treatment Usage Patterns, 2002 - 2011
Table 108: Schizophrenia Therapeutics Market, China, Sales Value ($m), 2011 - 2020
Table 109: Schizophrenia Therapeutics Market, China, Annual Cost of Therapy ($), 2011 - 2020
Table 110: Schizophrenia Therapeutics Market, China, Patient Volume , 2011 - 2020
Table 111: Schizophrenia Therapeutics Market, China, Treatment Usage Patterns, 2011 - 2020
Table 112: Schizophrenia Therapeutics Market, Russia, Sales Value ($m), 2002 - 2011
Table 113: Schizophrenia Therapeutics Market, Russia, Annual Cost of Therapy ($), 2002 - 2011
Table 114: Schizophrenia Therapeutics Market, Russia, Patient Volume , 2002 - 2011
Table 115: Schizophrenia Therapeutics Market, Russia, Treatment Usage Patterns, 2002 - 2011
Table 116: Schizophrenia Therapeutics Market, Russia, Sales Value ($m), 2011 - 2020
Table 117: Schizophrenia Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011 - 2020
Table 118: Schizophrenia Therapeutics Market, Russia, Patient Volume , 2011 - 2020
Table 119: Schizophrenia Therapeutics Market, Russia, Treatment Usage Patterns, 2011 - 2020
Table 120: Abilify Oral Dosage Regime
Table 121: Results CAITE Phase III, 2008
Table 122: Zyprexa Oral Dosage Regime
Table 123: Results CATIE Phase III, 2008
Table 124: Seroquel Oral Dosage Regime
Table 125: Results CATIE Phase III, 2008
Table 126: Geodon Oral Dosage Regime
Table 127: Results CATIE Phase III, 2008
Table 128: Invega Oral Dosage Regime
Table 129: Invega Sustenna Dosage Regime
Table 130: Schizophrenia Therapeutics Promising Drugs in Pipeline
Table 131: Schizophrenia Therapeutics - Safety and Efficacy Comparison of the Promising Drugs Under Clinical Development, 2011
Table 132: Cariprazine, Phase IIb Clinical Trials Results
Table 133: RG1678, Phase II Discontinuation Rates
Table 134: Schizophrenia Therapeutics - NDA Filed and Phase III Clinical Pipeline, 2011
Table 135: Schizophrenia Therapeutics - NDA Filed and Phase III Clinical Pipeline, 2011
Table 136: Schizophrenia Therapeutics - Phase II Clinical Pipeline, 2011
Table 137: Schizophrenia Therapeutics - Phase I Clinical Pipeline, 2011
Table 138: Schizophrenia Therapeutics - Preclinical and Discovery Pipeline, 2011
Table 139: Schizophrenia Therapeutics Market, Global, Clinical Trials by Status, January 2012
Table 140: Schizophrenia Therapeutics Market, Global, Clinical Trials by Country, January 2012
Table 141: Schizophrenia Therapeutics Market, Global, Clinical Trials by Phase, January 2012
Table 142: Schizophrenia Therapeutics Market, Global, Clinical Trials by Sponsor Type, January 2012
Table 143: Leading Sponsors of Clinical Trials by Number of Trials Sponsored, January 2012
Table 144: Schizophrenia Therapeutics Market, Global, Clinical Trials, Prominent Company Sponsors, January 2012 (Number of Trials)
Table 145: Schizophrenia Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, January 2012
Table 146: Schizophrenia, Global, Licensing Agreements, 2010-2011

List of Figures

Figure 1: Pictographic Representation of the Brain Suffering From Schizophrenia
Figure 2: Neurodevelopment of Schizophrenia
Figure 3: Symptoms of Schizophrenia
Figure 4: The Various Stages of Schizophrenia
Figure 5: IPAP Treatment Algorithm
Figure 6: Complexity of Schizophrenia
Figure 7: Overview of Psychosocial Treatments for Schizophrenia
Figure 8: Commonly Prescribed Drugs (Oral) for Schizophrenia - First Generation Antipsychotics
Figure 9: Commonly Prescribed Drugs (Oral) for Schizophrenia - Second Generation Antipsychotics
Figure 10: Schizophrenia, Novel Treatment Options
Figure 11: The Possible Effects of mGlu2/ 3 Receptor Agonists on Schizophrenia
Figure 12: Glycine Transporter Inhibitor: Novel Treatment for Schizophrenia
Figure 13: Schizophrenia Therapeutics Market, Global, Sales Value ($m), 2002 - 2011
Figure 14: Schizophrenia Therapeutics Market, Global, Sales Value ($m) by Country, 2002 - 2011
Figure 15: Schizophrenia Therapeutics Market, Global, Annual Cost of Therapy ($), 2002 - 2011
Figure 16: Schizophrenia Therapeutics Market, Global, Patient Volume, 2002 - 2011
Figure 17: Schizophrenia Therapeutics Market, Global, Treatment Usage Patterns, 2002 - 2011
Figure 18: Schizophrenia Therapeutics Market, Global, Market Drivers and Restraints, 2011
Figure 19: Schizophrenia Therapeutics Market, Global, the Impact of Historical Events on the Market, 2011
Figure 20: Schizophrenia Therapeutics Market, Global, Sales Value ($m), 2011 - 2020
Figure 21: Schizophrenia Therapeutics Market, Global, Sales Value ($m) by Country, 2011 - 2020
Figure 22: Schizophrenia Therapeutics Market, Global, Annual Cost of Therapy ($), 2011 - 2020
Figure 23: Schizophrenia Therapeutics Market, Global, Patient Volume, 2011 - 2020
Figure 24: Schizophrenia Therapeutics Market, Global, Treatment Usage Patterns, 2011 - 2020
Figure 25: Schizophrenia Therapeutics Market, Global, Future Market Drivers and Restraints,
2011 - 2020
Figure 26: Schizophrenia Therapeutics Market, Global, Drug Sales ($m), 2002-2020
Figure 27: Schizophrenia Therapeutics Market, The US, Sales Value ($m), 2002 - 2011
Figure 28: Schizophrenia Therapeutics Market, The US, Annual Cost of Therapy ($), 2002 - 2011
Figure 29: Schizophrenia Therapeutics Market, The US, Patient Volume, 2002 - 2011
Figure 30: Schizophrenia Therapeutics Market, The US, Treatment Usage Patterns, 2002 - 2011
Figure 31: Schizophrenia Therapeutics Market, The US, Market Drivers and Restraints, 2011
Figure 32: Schizophrenia Therapeutics Market, The US, the Impact of Historical Events on the Market, 2011
Figure 33: Schizophrenia Therapeutics Market, The US, Sales Value ($m), 2011 - 2020
Figure 34: Schizophrenia Therapeutics Market, The US, Annual Cost of Therapy ($), 2011 - 2020
Figure 35: Schizophrenia Therapeutics Market, The US, Patient Volume , 2011 - 2020
Figure 36: Schizophrenia Therapeutics Market, The US, Treatment Usage Patterns, 2011 - 2020
Figure 37: Schizophrenia Therapeutics Market, The US, Future Market Drivers and Restraints,
2011 - 2020
Figure 38: Schizophrenia Therapeutics Market, The US, Drug Sales ($m), 2002-2020
Figure 39: Schizophrenia Therapeutics Market, The UK, Sales Value ($m), 2002 - 2011
Figure 40: Schizophrenia Therapeutics Market, The UK, Annual Cost of Therapy ($), 2002 - 2011
Figure 41: Schizophrenia Therapeutics Market, The UK, Patient Volume , 2002 - 2011
Figure 42: Schizophrenia Therapeutics Market, The UK, Treatment Usage Patterns, 2002 - 2011
Figure 43: Schizophrenia Therapeutics Market, The UK, Market Drivers and Restraints, 2011
Figure 44: Schizophrenia Therapeutics Market, The UK, the Impact of Historical Events on the Market, 2011
Figure 45: Schizophrenia Therapeutics Market, The UK, Sales Value ($m), 2011 - 2020
Figure 46: Schizophrenia Therapeutics Market, The UK, Annual Cost of Therapy ($), 2011 - 2020
Figure 47: Schizophrenia Therapeutics Market, The UK, Patient Volume , 2011 - 2020
Figure 48: Schizophrenia Therapeutics Market, The UK, Treatment Usage Patterns, 2011 - 2020
Figure 49: Schizophrenia Therapeutics Market, The UK, Future Market Drivers and Restraints,
2011 - 2020
Figure 50: Schizophrenia Therapeutics Market, The UK, Drug Sales ($m), 2002-2020
Figure 51: Schizophrenia Therapeutics Market, Germany, Sales Value ($m), 2002 - 2011
Figure 52: Schizophrenia Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002 - 2011
Figure 53: Schizophrenia Therapeutics Market, Germany, Patient Volume , 2002 - 2011
Figure 54: Schizophrenia Therapeutics Market, Germany, Treatment Usage Patterns, 2002 - 2011
Figure 55: Schizophrenia Therapeutics Market, Germany, Market Drivers and Restraints, 2011
Figure 56: Schizophrenia Therapeutics Market, Germany, The Impact of Historical Events on the Market, 2011
Figure 57: Schizophrenia Therapeutics Market, Germany, Sales Value ($m), 2011 - 2020
Figure 58: Schizophrenia Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011 - 2020
Figure 59: Schizophrenia Therapeutics Market, Germany, Patient Volume , 2011 - 2020
Figure 60: Schizophrenia Therapeutics Market, Germany, Treatment Usage Patterns, 2011 - 2020
Figure 61: Schizophrenia Therapeutics Market, Germany, Future Market Drivers and Restraints,
2011 - 2020
Figure 62: Schizophrenia Therapeutics Market, Germany, Drug Sales ($m), 2001-2020
Figure 63: Schizophrenia Therapeutics Market, France, Sales Value ($m), 2002 - 2011
Figure 64: Schizophrenia Therapeutics Market, France, Annual Cost of Therapy ($), 2002 - 2010
Figure 65: Schizophrenia Therapeutics Market, France, Patient Volume , 2002 - 2011
Figure 66: Schizophrenia Therapeutics Market, France, Treatment Usage Patterns, 2002 - 2011
Figure 67: Schizophrenia Therapeutics Market, France, Market Drivers and Restraints, 2011
Figure 68: Schizophrenia Therapeutics Market, France, The Impact of Historical Events on the Market, 2011
Figure 69: Schizophrenia Therapeutics Market, France, Sales Value ($m), 2011 - 2020
Figure 70: Schizophrenia Therapeutics Market, France, Annual Cost of Therapy ($), 2011 - 2020
Figure 71: Schizophrenia Therapeutics Market, France, Patient Volume , 2011 - 2020
Figure 72: Schizophrenia Therapeutics Market, France, Treatment Usage Patterns, 2011 - 2020
Figure 73: Schizophrenia Therapeutics Market, France, Future Market Drivers and Restraints,
2011 - 2020
Figure 74: Schizophrenia Therapeutics Market, France, Drug Sales ($m), 2002-2020
Figure 75: Schizophrenia Therapeutics Market, Italy, Sales Value ($m), 2002 - 2011
Figure 76: Schizophrenia Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002 - 2011
Figure 77: Schizophrenia Therapeutics Market, Italy, Patient Volume , 2002 - 2011
Figure 78: Schizophrenia Therapeutics Market, Italy, Treatment Usage Patterns, 2002 - 2011
Figure 79: Schizophrenia Therapeutics Market, Italy, Market Drivers and Restraints, 2011
Figure 80: Schizophrenia Therapeutics Market, Italy, The Impact of Historical Events on the Market, 2011
Figure 81: Schizophrenia Therapeutics Market, Italy, Sales Value ($m), 2011 - 2020
Figure 82: Schizophrenia Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011 - 2020
Figure 83: Schizophrenia Therapeutics Market, Italy, Patient Volume , 2011 - 2020
Figure 84: Schizophrenia Therapeutics Market, Italy, Treatment Usage Patterns, 2011 - 2020
Figure 85: Schizophrenia Therapeutics Market, Italy, Future Market Drivers and Restraints, 2011 - 2020
Figure 86: Schizophrenia Therapeutics Market, Italy, Drug Sales ($m), 2002-2020
Figure 87: Schizophrenia Therapeutics Market, Spain, Sales Value ($m), 2002 - 2011
Figure 88: Schizophrenia Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002 - 2011
Figure 89: Schizophrenia Therapeutics Market, Spain, Patient Volume, 2002 - 2011
Figure 90: Schizophrenia Therapeutics Market, Spain, Treatment Usage Patterns, 2002 - 2011
Figure 91: Schizophrenia Therapeutics Market, Spain, Market Drivers and Restraints, 2011
Figure 92: Schizophrenia Therapeutics Market, Spain, The Impact of Historical Events on the Market, 2011
Figure 93: Schizophrenia Therapeutics Market, Spain, Sales Value ($m), 2011 - 2020
Figure 94: Schizophrenia Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011 - 2020
Figure 95: Schizophrenia Therapeutics Market, Spain, Patient Volume , 2011 - 2020
Figure 96: Schizophrenia Therapeutics Market, Spain, Treatment Usage Patterns, 2011 - 2020
Figure 97: Schizophrenia Therapeutics Market, Spain, Future Market Drivers and Restraints,
2011 - 2020
Figure 98: Schizophrenia Therapeutics Market, Spain, Drug Sales ($m), 2002-2020
Figure 99: Schizophrenia Therapeutics Market, Japan, Sales Value ($m), 2002 - 2011
Figure 100: Schizophrenia Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002 - 2011
Figure 101: Schizophrenia Therapeutics Market, Japan, Patient Volume, 2002 - 2011
Figure 102: Schizophrenia Therapeutics Market, Japan, Treatment Usage Patterns, 2002 - 2011
Figure 103: Schizophrenia Therapeutics Market, Japan, Market Drivers and Restraints, 2011
Figure 104: Schizophrenia Therapeutics Market, Japan, The Impact of Historical Events on the Market, 2011
Figure 105: Schizophrenia Therapeutics Market, Japan, Sales Value ($m), 2011 - 2020
Figure 106: Schizophrenia Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011 - 2020
Figure 107: Schizophrenia Therapeutics Market, Japan, Patient Volume , 2011 - 2020
Figure 108: Schizophrenia Therapeutics Market, Japan, Treatment Usage Patterns, 2011 - 2020
Figure 109: Schizophrenia Therapeutics Market, Japan, Future Market Drivers and Restraints,
2011 - 2020
Figure 110: Schizophrenia Therapeutics Market, Japan, Drug Sales ($m), 2002-2020
Figure 111: Schizophrenia Therapeutics Market, Brazil, Sales Value ($m), 2002 - 2011
Figure 112: Schizophrenia Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002 - 2011
Figure 113: Schizophrenia Therapeutics Market, Brazil, Patient Volume , 2002 - 2011
Figure 114: Schizophrenia Therapeutics Market, Brazil, Treatment Usage Patterns, 2002 - 2011
Figure 115: Schizophrenia Therapeutics Market, Brazil, Market Drivers and Restraints, 2011
Figure 116: Schizophrenia Therapeutics Market, Brazil, The Impact of Historical Events on the Market, 2011
Figure 117: Schizophrenia Therapeutics Market, Brazil, Sales Value ($m), 2011 - 2020
Figure 118: Schizophrenia Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011 - 2020
Figure 119: Schizophrenia Therapeutics Market, Brazil, Patient Volume , 2011 - 2020
Figure 120: Schizophrenia Therapeutics Market, Brazil, Treatment Usage Patterns, 2011 - 2020
Figure 121: Schizophrenia Therapeutics Market, Brazil, Future Market Drivers and Restraints,
2011 - 2020
Figure 122: Schizophrenia Therapeutics Market, India, Sales Value ($m), 2002 - 2011
Figure 123: Schizophrenia Therapeutics Market, India, Annual Cost of Therapy ($), 2002 - 2011
Figure 124: Schizophrenia Therapeutics Market, India, Patient Volume , 2002 - 2011
Figure 125: Schizophrenia Therapeutics Market, India, Treatment Usage Patterns, 2002 - 2011
Figure 126: Schizophrenia Therapeutics Market, India, Market Drivers and Restraints, 2011
Figure 127: Schizophrenia Therapeutics Market, India, The Impact of Historical Events on the Market, 2011
Figure 128: Schizophrenia Therapeutics Market, India, Sales Value ($m), 2011 - 2020
Figure 129: Schizophrenia Therapeutics Market, India, Annual Cost of Therapy ($), 2011 - 2020
Figure 130: Schizophrenia Therapeutics Market, India, Patient Volume , 2011 - 2020
Figure 131: Schizophrenia Therapeutics Market, India, Treatment Usage Patterns, 2011 - 2020
Figure 132: Schizophrenia Therapeutics Market, India, Future Market Drivers and Restraints, 2011 - 2020
Figure 133: Schizophrenia Therapeutics Market, China, Sales Value ($m), 2002 - 2011
Figure 134: Schizophrenia Therapeutics Market, China, Annual Cost of Therapy ($), 2002 - 2011
Figure 135: Schizophrenia Therapeutics Market, China, Patient Volume , 2002 - 2011
Figure 136: Schizophrenia Therapeutics Market, China, Treatment Usage Patterns, 2002 - 2011
Figure 137: Schizophrenia Therapeutics Market, China, Market Drivers and Restraints, 2011
Figure 138: Schizophrenia Therapeutics Market, China, The Impact of Historical Events on the Market, 2011
Figure 139: Schizophrenia Therapeutics Market, China, Sales Value ($m), 2011 - 2020
Figure 140: Schizophrenia Therapeutics Market, China, Annual Cost of Therapy ($), 2011 - 2020
Figure 141: Schizophrenia Therapeutics Market, China, Patient Volume , 2011 - 2020
Figure 142: Schizophrenia Therapeutics Market, China, Treatment Usage Patterns, 2011 - 2020
Figure 143: Schizophrenia Therapeutics Market, China, Future Market Drivers and Restraints,
2011 - 2020
Figure 144: Schizophrenia Therapeutics Market, Russia, Sales Value ($m), 2002 - 2011
Figure 145: Schizophrenia Therapeutics Market, Russia, Annual Cost of Therapy ($), 2002 - 2011
Figure 146: Schizophrenia Therapeutics Market, Russia, Patient Volume , 2002 - 2011
Figure 147: Schizophrenia Therapeutics Market, Russia, Treatment Usage Patterns, 2002 - 2011
Figure 148: Schizophrenia Therapeutics Market, Russia, Market Drivers and Restraints, 2011
Figure 149: Schizophrenia Therapeutics Market, Russia, the Impact of Historical Events on the Market, 2011
Figure 150: Schizophrenia Therapeutics Market, Russia, Sales Value ($m), 2011 - 2020
Figure 151: Schizophrenia Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011 - 2020
Figure 152: Schizophrenia Therapeutics Market, Russia, Patient Volume , 2011 - 2020
Figure 153: Schizophrenia Therapeutics Market, Russia, Treatment Usage Patterns, 2011 - 2020
Figure 154: Schizophrenia Therapeutics Market, Russia, Future Market Drivers and Restraints,
2011 - 2020
Figure 155: Opportunity and Unmet Need in the Schizophrenia Therapeutics Market, 2010
Figure 156: Strategic Competitor Assessment of the Major Marketed Products in Schizophrenia, 2010
Figure 157: Schizophrenia Therapeutics Market, Global, Abilify, Sales Forecast ($m), 2002-2020
Figure 158: Schizophrenia Therapeutics Market, Global, Abilify, Market Share Analysis (%), 2011
Figure 159: Schizophrenia Therapeutics Market, Global, Zyprexa, Sales Forecast ($m), 2002-2018
Figure 160: Schizophrenia Therapeutics Market, Global, Zyprexa, Market Share Analysis (%), 2011
Figure 161: Schizophrenia Therapeutics Market, Global, Seroquel, Sales Forecast ($m), 2002-2016
Figure 162: Schizophrenia Therapeutics Market, Global, Seroquel, Market Share Analysis (%), 2011
Figure 163: Schizophrenia Therapeutics Market, Global, Geodon, Sales Forecast ($m), 2002-2017
Figure 164: Schizophrenia Therapeutics Market, Global, Geodon, Market Share Analysis (%), 2011
Figure 165: Schizophrenia Therapeutics Market, Global, Invega, Sales Forecast ($m), 2007-2020
Figure 166: Schizophrenia Therapeutics Market, Global, Invega Sustenna, Sales Forecast ($m),
2009-2020
Figure 167: Schizophrenia Therapeutics Market, Global, Invega, Market Share Analysis (%), 2011
Figure 168: Schizophrenia Therapeutics Market, Global, Invega Sustenna, Market Share Analysis (%), 2011
Figure 169: Schizophrenia Therapeutics Market, Global, Latuda, Sales Forecast ($m), 2011-2020
Figure 170: Technology Trends Analytic Framework of the Schizophrenia Pipeline, 2011
Figure 171: Technology Trends Analytic Framework Description of the Schizophrenia Pipeline, 2011
Figure 172: Schizophrenia Therapeutics Market, Global, Cariprazine, Sales Forecast ($m), 2013-2020
Figure 173: Schizophrenia Therapeutics Market, Global, RG1678, Sales Forecast ($m), 2014-2020
Figure 174: Schizophrenia Therapeutics Market, Global, Zicronapine, Sales Forecast ($m), 2014-2020
Figure 175: Schizophrenia Therapeutics Market - Clinical Pipeline by Phases of Development, 2011
Figure 176: Schizophrenia Therapeutics Market - Clinical Pipeline by Mechanisms of Action Phases of Development, 2011
Figure 177: Schizophrenia Therapeutics Market - Pipeline by Clinical Phase of Development, 2011
Figure 178: Schizophrenia Therapeutics Market, Global, Clinical Trials by Status, January 2012
Figure 179: Schizophrenia Therapeutics Market, Global, Clinical Trials by Country, January 2012
Figure 180: Schizophrenia Therapeutics Market, Global, Clinical Trials by Phase, January 2012
Figure 181: Schizophrenia Therapeutics Market, Global, Clinical Trials by Sponsor Type, January 2012
Figure 182: Schizophrenia Therapeutics Market, Global, Clinical Trials by Leading Sponsor, January 2012
Figure 183: Schizophrenia Therapeutics Market, Global, Clinical Trials, Prominent Company Sponsors, January 2012
Figure 184: Schizophrenia Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, January 2012
Figure 185: Implications for Future Market Competition in the Schizophrenia Therapeutics Market, 2012
Figure 186: Schizophrenia Therapeutics Market, Pipeline by Company, 2011
Figure 187: Schizophrenia, Global, Pfizer, SWOT Analysis 2011
Figure 188: Schizophrenia, Global, Lundbeck , SWOT Analysis 2011
Figure 189: Schizophrenia, Gedeon Richter Plc, SWOT Analysis 2011
Figure 190: Schizophrenia, F. Hoffmann-La Roche Ltd., SWOT Analysis 2011
Figure 191: Schizophrenia, Global, BMS, SWOT Analysis 2011
Figure 192: Schizophrenia, Eli Lilly and Co., SWOT Analysis 2011
Figure 193: Schizophrenia, Otsuka Holdings Co.., SWOT Analysis 2011
Figure 194: Schizophrenia, Alexza Pharmaceuticals SWOT Analysis 2011
Figure 195: Schizophrenia, the US, Inputs from Physician Interviews, 2011
Figure 196: Schizophrenia, the UK, Inputs from Physician Interviews, 2011
Figure 197: Schizophrenia, Germany, Inputs from Physician Interviews, 2011
Figure 198: Schizophrenia, France, Inputs from Physician Interviews, 2011
Figure 199: Schizophrenia, India, Inputs from Physician Interviews, 2011
Figure 200: GlobalData Market Forecasting Model